Probiotic Supplementation in Morbid Obese Patients Undergoing One Anastomosis Gastric Bypass-Mini Gastric Bypass (OAGB-MGB) Surgery: a Randomized, Double-Blind, Placebo-Controlled, Clinical Trial

Karbaschian, Zohreh; Mokhtari, Zeinab; Pazouki, Abdolreza; Kabir, Ali; Mahdi, Hedayati; Moghadam, Somayeh Soleymanzadeh; Mirmiran, Parvin; Hekmatdoost, Azita

doi:10.1007/s11695-018-3280-2

Cited by 41 publications

(41 citation statements)

References 52 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We identified 1934 records, from which we selected 986 individual abstracts and 161 potentially relevant articles for full review (figure 1). We identified 105 articles19 25–128 reporting data from 99 different research studies including 111 different randomised comparisons of probiotics versus control (further called randomised clinical trials [RCTs], see online supplementary table 1-2) with the following outcomes: BW (number of RCTs: k=58, n=3422 individuals, median=77.4 kg), BMI (k=68, n=4015, 28.2 kg/m²), WC (k=26, n=1583, 98.8 cm); BFM (k=27, n=1562, 27.8 kg), SAT and VAT (k=5, n=543, 192.4 cm² and 114.7 cm², respectively), FG (k=83, n=5188, 6.1 mmol), HbA 1c (k=28, n=1796, 6.3%), INS (k=63, n=3854, 11.0 mU/L), HOMA-IR (k=52, n=3513, 3.2), CRP (k=41, n=2376, 3.6 mg/L), TG (k=74, n=4461, 145.4 mg/dL), ALAT (k=26, n=1466, 38.6 IU/L), ASAT (k=23, n=1340, 36.1 IU/L) and GGT (k=14, n=816, 41.5 IU/L). The median duration of the follow-up was 8 weeks (range: 2–28 weeks), probiotics dose ranged from 10 7 to 10 12 CFU daily, and 43 trials were conducted in one country (Iran).…”

Section: Resultsmentioning

confidence: 99%

“…Different probiotic species and strains may have multiple modes of actions affecting sugar digestion and absorption,136 fat absorption,106 gut barrier function,112 115 137 low-grade inflammation, 39 71 81 99 110 111 116 138 bile acid metabolism,97 139 incretin secretion120 and gut microbiota ecosystems19 44 87 115 119 and, in particular, short chain fatty acid production 121. It is reasonable to anticipate that these multiple effects may combine to induce significant effects, particularly in the case of multispecies mixes.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Impact of bacterial probiotics on obesity, diabetes and non-alcoholic fatty liver disease related variables: a systematic review and meta-analysis of randomised controlled trials

et al. 2019

View full text Add to dashboard Cite

ObjectiveTo systematically review the effect of oral intake of bacterial probiotics on 15 variables related to obesity, diabetes and non-alcoholic fatty liver disease.DesignSystematic review and meta-analysis.Data sourcesMedline, EMBASE and COCHRANE from 1990 to June 2018.Eligibility criteriaRandomised controlled trials (≥14 days) excluding hypercholesterolaemia, alcoholic liver disease, polycystic ovary syndrome and children <3 years.ResultsOne hundred and five articles met inclusion criteria, representing 6826 subjects. In overweight but not obese subjects, probiotics induced improvements in: body weight (k=25 trials, d=−0.94 kg mean difference, 95% CI −1.17 to −0.70, I²=0.0%), body mass index (k=32, d=−0.55 kg/m², 95% CI −0.86 to −0.23, I²=91.9%), waist circumference (k=13, d=−1.31 cm, 95% CI −1.79 to −0.83, I²=14.5%), body fat mass (k=11, d=−0.96 kg, 95% CI −1.21 to −0.71, I²=0.0%) and visceral adipose tissue mass (k=5, d=−6.30 cm², 95% CI −9.05 to −3.56, I²=0.0%). In type 2 diabetics, probiotics reduced fasting glucose (k=19, d=−0.66 mmol/L, 95% CI −1.00 to −0.31, I²=27.7%), glycated haemoglobin (k=13, d=−0.28 pp, 95% CI −0.46 to −0.11, I²=54.1%), insulin (k=13, d=−1.66 mU/L, 95% CI −2.70 to −0.61, I²=37.8%) and homeostatic model of insulin resistance (k=10, d=−1.05 pp, 95% CI −1.48 to −0.61, I²=18.2%). In subjects with fatty liver diseases, probiotics reduced alanine (k=12, d=−10.2 U/L, 95% CI −14.3 to −6.0, I²=93.50%) and aspartate aminotransferases (k=10, d=−9.9 U/L, 95% CI −14.1 to -5.8, I²=96.1%). These improvements were mostly observed with bifidobacteria (Bifidobacterium breve, B. longum), Streptococcus salivarius subsp. thermophilus and lactobacilli (Lactobacillus acidophilus, L. casei, L. delbrueckii) containing mixtures and influenced by trials conducted in one country.ConclusionsThe intake of probiotics resulted in minor but consistent improvements in several metabolic risk factors in subjects with metabolic diseases.Trial registration numberCRD42016033273.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Impact of bacterial probiotics on obesity, diabetes and non-alcoholic fatty liver disease related variables: a systematic review and meta-analysis of randomised controlled trials

et al. 2019

View full text Add to dashboard Cite

show abstract

“…Familact (Zist Takhmir Co., Tehran, Iran) is a probiotic mixture supplement that has shown efficacy in several diseases . Therefore, we conducted this randomized crossover clinical trial.…”

Section: Introductionmentioning

confidence: 99%

“…Familact (Zist Takhmir Co., Tehran, Iran) is a probiotic mixture supplement that has shown efficacy in several diseases. [13][14][15][16][17][18] Therefore, we conducted this randomized crossover clinical trial. The aim of this study was to assess the impact of add-on probiotic supplement on PAR symptoms and on the QoL of patients.…”

Section: Introductionmentioning

confidence: 99%

Add‐on probiotics in patients with persistent allergic rhinitis: A randomized crossover clinical trial

et al. 2019

View full text Add to dashboard Cite

Objectives Current medications for allergic rhinitis (AR) may have undesirable side effects that could affect quality of life (QoL). Probiotics could be an alternative in these patients. The aim of this study was to assess the impact of add‐on probiotics on symptoms and QoL of patients. Methods In this randomized crossover clinical trial, patients with persistent AR were included. Each subject received budesonide with probiotic supplements (BP) or budesonide with placebo for 8 weeks (B), then vice versa for a further 8 weeks. There was an 8‐week washout. The primary outcome was the change of the Short Form 36‐Item Health Survey (SF‐36) score. The secondary outcomes were assessed by the Sinonasal Outcome Test‐22 (SNOT‐22) and the Control of Allergic Rhinitis and Asthma Test (CARAT) questionnaires. Results A total of 152 subjects (30.1 ± 7.6 years) completed the study. The SF‐36 score in both groups showed improvement compared with baseline values. Treatment BP was more effective than that of B. The Cohen's d and the number needed to treat for Physical Component Scales of SF‐36 were 0.40 and 10.77, respectively. These values for Mental Component Scales were 0.33 and 12.61, respectively. Also, treatment BP showed more reduction in the score of SNOT‐22 and CARAT. Conclusion This study showed that the addition of probiotics to budesonide significantly improved QoL in persistent AR patients. However, the clinical situation of these patients may be not very representative of AR patients in general population. Further studies are recommended. Level of Evidence 1bLaryngoscope, 129:1744–1750, 2019

show abstract

“…Patients administered microecological preparations following bariatric surgery show benefits in their quality of life (QoL), excess weight loss (EWL), vitamin accessibility, and inflammatory marker expression. Karbaschian et al [19] showed that probiotics stimulate weight loss in patients undergoing gastric bypass. However, another study [20] showed that administering probiotics does not improve anthropometric measurements in patients following laparoscopic SG.…”

Section: Introductionmentioning

confidence: 99%

Effects of Microecological Preparations on Obese Patients after Bariatric Surgery: A Systematic Review and Meta‐Analysis

Zhu

Ren

Zang

et al. 2020

Evidence-Based Complementary and Alternative Medicine

View full text Add to dashboard Cite

Vitamin deficiency, bacterial overgrowth, and gastrointestinal symptoms can be detected in obese patients after bariatric surgery that influences their quality of life (QoL) and weight. It is unclear if microecological preparations benefit obese patients following bariatric surgery. The aim of this study is to investigate the effects of microecological preparations on QoL, excess weight loss (EWL), and levels of vitamin B12 and inflammatory markers. We searched seven databases to identify reports published till December 1, 2019, and included randomized controlled trials investigating the effects of microecological preparations in obese adults undergoing bariatric surgery. The primary outcomes included QoL and EWL, while secondary outcomes comprised serum levels of vitamin B12, interleukin 6, TNF-α, and C-reactive protein (CRP). Study bias was analyzed using the Cochrane risk-of-bias tool. Statistical analyses were performed using Review Manager. The mean difference in outcomes was calculated using standardized mean difference (SMD) with a confidence interval (CI) of 95%. A majority of the studies showed a low or moderate risk of bias. Meta-analysis showed significantly higher levels of vitamin B12 in postoperative patients administered with microecological preparations (SMD = 0.52; 95% CI = 0.08–0.95; P=0.02). There were no significant differences in QoL (SMD = −0.14; 95% CI = −0.45–0.17; P=0.38), EWL (SMD = 0.45; 95% CI = −0.16–1.05; P=0.15), and levels of TNF-α (SMD = −0.29; 95% CI = −0.64–0.05; P=0.09), interleukin 6 (SMD = −0.1; 95% CI = −0.81–0.61; P=0.78]), and CRP (SMD = 0.02; 95% CI = −0.32–0.36; P=0.93). The trials examined indicated that microecological preparations had limited efficacy in improving QoL, EWL, and inflammatory response, but they stimulated the synthesis of vitamin B12. This may help in designing efficient microecological preparations to supplement bariatric surgery in obese individuals.

show abstract

Probiotic Supplementation in Morbid Obese Patients Undergoing One Anastomosis Gastric Bypass-Mini Gastric Bypass (OAGB-MGB) Surgery: a Randomized, Double-Blind, Placebo-Controlled, Clinical Trial

Abstract: This study has been registered at Clinicaltrial.gov with registration number NCT02708589.

Cited by 41 publications

References 52 publications

Impact of bacterial probiotics on obesity, diabetes and non-alcoholic fatty liver disease related variables: a systematic review and meta-analysis of randomised controlled trials

Impact of bacterial probiotics on obesity, diabetes and non-alcoholic fatty liver disease related variables: a systematic review and meta-analysis of randomised controlled trials

Add‐on probiotics in patients with persistent allergic rhinitis: A randomized crossover clinical trial

Effects of Microecological Preparations on Obese Patients after Bariatric Surgery: A Systematic Review and Meta‐Analysis

Contact Info

Product

Resources

About